Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$5.06 USD
+0.03 (0.60%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $5.03 -0.03 (-0.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Champions Oncology, Inc falls in the month of April .
All items in Millions except EPS data.
4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | 4/30/19 | |
---|---|---|---|---|---|
Sales | 54 | 49 | 41 | 32 | 27 |
Cost Of Goods | 30 | 24 | 21 | 17 | 14 |
Gross Profit | 24 | 25 | 20 | 15 | 13 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 25 | 19 | 17 | 13 |
Income After Depreciation & Amortization | -5 | 1 | 0 | -2 | 0 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -5 | 1 | 0 | -2 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -5 | 1 | 0 | -2 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -5 | 1 | 0 | -2 | 0 |
Depreciation Footnote | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | 4/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | 2 | 2 | -1 | 1 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -5 | 1 | 0 | -2 | 0 |
Earnings Per Share Data | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | 4/30/19 |
---|---|---|---|---|---|
Average Shares | 13.54 | 14.16 | 14.57 | 11.84 | 14.10 |
Diluted EPS Before Non-Recurring Items | -0.39 | 0.04 | 0.02 | -0.17 | 0.01 |
Diluted Net EPS (GAAP) | -0.39 | 0.04 | 0.02 | -0.17 | 0.01 |
Fiscal Year end for Champions Oncology, Inc falls in the month of April .
All items in Millions except EPS data.
1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 | |
---|---|---|---|---|---|
Sales | 12.02 | 11.57 | 12.56 | 13.07 | 12.77 |
Cost Of Goods | 7.85 | 6.62 | 7.68 | 7.34 | 7.70 |
Gross Profit | 4.17 | 4.96 | 4.88 | 5.73 | 5.07 |
SG&A, R&D, and Dept/Amort Expenses | 6.75 | 6.92 | 7.43 | 7.45 | 7.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.58 | -1.96 | -2.55 | -1.72 | -2.46 |
Non-Operating Income | 0.06 | -0.11 | 0.01 | -0.02 | 0.04 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.52 | -2.06 | -2.54 | -2.54 | -2.42 |
Income Taxes | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.53 | -2.07 | -2.57 | -2.56 | -2.44 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.53 | -2.07 | -2.57 | -2.56 | -2.44 |
Earnings Per Share Data | 1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 |
---|---|---|---|---|---|
Average Shares | 13.59 | 13.50 | 13.51 | 13.56 | 13.56 |
Diluted EPS Before Non-Recurring Items | -0.19 | -0.15 | -0.19 | -0.19 | -0.18 |
Diluted Net EPS (GAAP) | -0.19 | -0.15 | -0.19 | -0.19 | -0.18 |